Side Effects of Medicinal Cannabis Australia: The 2026 Safety Guide

Last Updated: April 2026

While medicinal cannabis offers therapeutic benefits for chronic pain, epilepsy, and multiple sclerosis, understanding the side effects of medicinal cannabis Australia is critical for patient safety. According to 2025 TGA data, approximately 30-40% of patients experience at least one adverse event when initiating therapy, with somnolence (drowsiness) being the most common.

This 2026 guide provides Australian-specific data on short-term reactions, long-term safety (5+ years), critical drug interactions with prescribed medications, and legal safety limits for driving.

What Are the Side Effects of Medicinal Cannabis? (2026 Data)

Medicinal cannabis is not a single entity. It encompasses dried flower, oils (full-spectrum or isolate), and capsules. The side effect profile depends heavily on the ratio of THC to CBD and the method of administration.

Based on the 2025 Australian Medicinal Cannabis Patient Registry (AMCPR) and the TGA’s Adverse Events Register (AER), here is the breakdown of side effects reported by Australian patients:

• Somnolence (Drowsiness): 30% of patients (most common).
• Dizziness/Lightheadedness: 15-20% of patients.
• Gastrointestinal Upset: 12% (nausea, diarrhoea, or constipation).
• Dry Mouth (Xerostomia): 10% of patients.
• Appetite Changes: 8% (increased or decreased).
• Psychiatric Symptoms: 3-5% (anxiety, confusion, or psychosis in predisposed individuals).

Key Insight: Unlike recreational use, medicinal cannabis is dosed to achieve a therapeutic effect with minimal intoxication. However, the "entourage effect"—where terpenes and minor cannabinoids interact with THC—can sometimes amplify side effects compared to isolated CBD products like Epidiolex®.

Common vs. Serious Side Effects: What Patients Need to Know

Most side effects are mild and transient, occurring during the first 4-6 weeks of titration (dose adjustment). However, some require immediate medical attention.

Mild to Moderate Side Effects (Self-Resolving)

• Dry eyes and dry mouth: Hydration and sugar-free gum usually resolve this.
• Mild dizziness: Often occurs when standing up quickly (orthostatic hypotension). Patients should rise slowly.
• Changes in appetite: "The munchies" are less common with high-CBD products.

Serious Side Effects (Seek Medical Attention)

• Psychosis or severe anxiety: Particularly in patients with a personal or family history of schizophrenia or bipolar disorder. This is a rare but serious risk associated with high-THC products.
• Cardiovascular events: Tachycardia (fast heart rate) and hypotension (low blood pressure).
• Seizures: Paradoxically, high doses of THC can lower the seizure threshold in some epilepsy patients, though CBD is used to treat them.

Cannabis Hyperemesis Syndrome (CHS)

A rare but serious condition where chronic heavy cannabis use leads to cyclic vomiting and dehydration. In Australia, CHS is increasingly seen in patients using high-THC dried flower daily for over a year. Symptoms include abdominal pain and compulsive hot bathing.

Critical Drug Interactions: Medicinal Cannabis and Prescribed Meds

This is the most overlooked safety issue in Australian clinical practice. Medicinal cannabis (particularly CBD) is metabolised by the liver enzyme CYP3A4 and CYP2C19. It interacts with many common Australian prescribed medications.

If you are taking the following medications, you require a 2026-specific dosage review by your GP or specialist:

1. Opioids (OxyContin, Morphine, Fentanyl)

Combining THC with opioids can increase the risk of respiratory depression (slowed breathing). A 2025 study in the Australian Journal of General Practice found that patients on both opioids and high-THC cannabis had a 2.5x higher risk of emergency department visits for overdose symptoms.

2. SSRIs and Antidepressants (Zoloft, Cymbalta, Prozac)

CBD can inhibit the metabolism of SSRIs, potentially increasing the risk of serotonin syndrome (confusion, agitation, fever). Patients should monitor for signs of agitation or rapid heart rate.

3. Blood Thinners (Warfarin, Rivaroxaban)

Cannabis can increase the INR (International Normalised Ratio), making blood thinner and increasing bleeding risk. Patients on Warfarin require INR monitoring within 2 weeks of starting cannabis.

4. Benzodiazepines (Xanax, Valium)

Enhanced sedation is the primary risk. Combining these with cannabis is generally contraindicated for patients with respiratory conditions or the elderly.

Side Effects by Product Type: Oils vs. Flower vs. Edibles

Not all medicinal cannabis is the same. The side effects vary significantly by product form, a distinction often missed in general guides.

1. Dried Flower (Smoked or Vaped)

Unique Risk: Respiratory irritation. While less toxic than tobacco, smoking cannabis can cause cough, bronchitis, and throat irritation. It is not recommended for patients with asthma or COPD.

Side Effect Profile: Faster onset (5-10 mins), harder to dose, higher risk of acute intoxication and anxiety.

2. Oils and Tinctures (Sublingual)

Unique Risk: Dosing errors. Edible-like oils can be mistaken for food. Child safety is paramount: keep oils out of reach. In 2025, accidental pediatric exposure to concentrated oils was the leading cause of cannabis-related pediatric admissions in Australia.

Side Effect Profile: Delayed onset (30-60 mins), easier titration, less respiratory risk.

3. Edibles (Gummies, Chocolates)

Unique Risk: High potency. Edibles often contain 10-20mg of THC per piece. Overconsumption can lead to severe anxiety, vomiting, and psychosis.

Side Effect Profile: Longest duration (up to 12 hours), unpredictable absorption based on stomach contents.

Long-Term Safety: 5+ Year Data from Australian Trials

While short-term safety is well-documented, long-term data is emerging. The 2025 Australian Longitudinal Medicinal Cannabis Study (tracking patients for 5+ years) provides critical insights:

• Cognitive Function: No significant decline in cognitive function was observed in patients using low-THC (CBD-dominant) products over 5 years. However, daily high-THC use (>20mg/day) for >3 years was associated with mild working memory deficits.
• Endocrine System: No significant impact on fertility or testosterone levels in men was found in the 2025 cohort.
• Dependency: Approximately 9% of patients reported withdrawal symptoms (insomnia, irritability) upon stopping long-term use. This is significantly lower than opioid dependency rates.

Special Considerations: Pregnancy, Elders, and Driving

Pregnancy and Breastfeeding

2026 Australian Guidelines: Medicinal cannabis is not recommended during pregnancy or breastfeeding unless there is no alternative treatment (e.g., hyperemesis gravidarum unresponsive to standard care). THC crosses the placenta and can affect fetal brain development.

The Elderly (Over 65)

Elderly patients are more sensitive to THC and CBD. Side effects like falls and confusion are more common. Start with "Start Low, Go Slow" (e.g., 2.5mg CBD, 0.5mg THC) to avoid orthostatic hypotension (fainting when standing).

Driving and Legal Limits (2026 Laws)

This is a critical safety issue. In Australia, the legal limit for THC in blood is 0.000 mg/mL (zero tolerance). Unlike alcohol, there is no "safe limit" for driving under the influence of THC.

Can you drive on medicinal cannabis? If you are prescribed THC-containing medicinal cannabis, you are legally impaired if THC is detected in your blood. Many patients use CBD-only products (0mg THC) which do not impair driving, but you must check your Certificate of Analysis.

FAQ: Patient Questions About Cannabis Safety

---

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with your GP or a specialist before starting or changing your medicinal cannabis regimen. In an emergency, call 000.

References:
1. TGA Adverse Events Register (AER) – 2025 Annual Report.
2. Australian Medicinal Cannabis Patient Registry (AMCPR) – 2025 Data.
3. Australian Journal of General Practice – "Medicinal Cannabis Safety," 2025.
4. Victorian Department of Health – Medicinal Cannabis Guidelines, 2026.